<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="1" offset="0" totalResults="1"><SearchResults><Drug id="90973" name="CyTIX-01" lastModificationDate="2017-02-15T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Cell-Therapy Technology Institute, Inc</CompanyOriginator><CompaniesPrimary><Company>Cell-Therapy Technology Institute, Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Glioma</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>Cell-Therapy Technology Institute (CyTIX) is developing CyTIX-01, a dendritic cell (DC)-tumor cell fusion vaccine, administered with recombinant human interleukin 12 (rhIL12) adjuvant, for the potential treatment of glioma [ 1549331 ], [ 1549315 ], [ 1900250 ]. In April 2014, development was ongoing and the company was seeking to outlicense the vaccine [ 1549331 ], [ 1549315 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Dendritic cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2014-04-23T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="0" label="&lt; 100"/><FilterOption count="0" label="≥ 100 and  250"/><FilterOption count="0" label="≥ 250 and  500"/><FilterOption count="0" label="≥ 500 and  1000"/><FilterOption count="0" label="≥ 1000"/></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="3"><FilterOption id="1545" count="1" label="Anticancer"/><FilterOption id="102926" count="1" label="Dendritic cell vaccine"/><FilterOption id="12379" count="1" label="Therapeutic vaccine"/></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="0" label="&lt; 100"/><FilterOption count="0" label="≥ 100 and  250"/><FilterOption count="0" label="≥ 250 and  500"/><FilterOption count="0" label="≥ 500 and  1000"/><FilterOption count="0" label="≥ 1000"/></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="1" label="= 0"/><FilterOption count="0" label="&gt; 1 and ≤ 1"/><FilterOption count="0" label="&gt; 2 and ≤ 2"/><FilterOption count="0" label="&gt; 3 and ≤ 3"/><FilterOption count="0" label="&gt; 4 and ≤ 4"/><FilterOption count="0" label="&gt; 5 and ≤ 5"/><FilterOption count="0" label="&gt; 6 and ≤ 10"/><FilterOption count="0" label="&gt; 11"/></Filter><Filter label="Technologies" name="technologies" total="3"><FilterOption id="761" count="1" label="Biological therapeutic"/><FilterOption id="570" count="1" label="Cell therapy"/><FilterOption id="766" count="1" label="Parenteral formulation unspecified"/></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="1"><FilterOption count="1" label="2014-04-23"/></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="1"><FilterOption count="1" label="No"/></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="1"><FilterOption id="1108" count="1" label="Glioma"/></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="1"><FilterOption id="1" count="1" label="Orphan Drug"/></Filter><Filter label="Primary Companies" name="companiesPrimary" total="1"><FilterOption id="1095289" count="1" label="Cell-Therapy Technology Institute, Inc"/></Filter><Filter label="Highest Phase" name="phaseHighest" total="1"><FilterOption id="C2" count="1" label="Phase 2 Clinical"/></Filter></Filters></drugResultsOutput>